Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Study to Evaluate the Catheter Robotics Amigo for Performing Right-Sided Electrophysiology Mapping Studies

This study has been completed.
Sponsor:
Collaborator:
Medpace, Inc.
Information provided by (Responsible Party):
Catheter Robotics, Inc.
ClinicalTrials.gov Identifier:
NCT01139814
First received: June 7, 2010
Last updated: April 9, 2013
Last verified: April 2013
Results First Received: March 1, 2013  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Conditions: Atrial Flutter
Ventricular Tachycardia
Intervention: Device: Amigo catheter robot

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Intent-to-Treat

Subject was evaluated for the study criteria on the day of procedure, Investigator positioned the mapping catheter in the right heart, and connected the mapping catheter to the Amigo RCS.

Amigo RCS is an accessory for use in the cardiac EP setting to allow the operator to manipulate a steerable cardiac catheter and perform a conventional electrophysiology procedure. The intent of the device is to allow the operator to complete the procedure in a conventional x-ray guided EP lab. Catheter control can be performed while standing (or sitting) some distance from the subject to minimize absorbed radiology dose and minimize operator fatigue from standing for long periods of time with the standard lead aprons/personal protection devices.


Participant Flow:   Overall Study
    Intent-to-Treat  
STARTED     181  
COMPLETED     181  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Intent-to-Treat Subject was evaluated for the study criteria on the day of procedure, Investigator positioned the mapping catheter in the right heart, and connected the mapping catheter to the Amigo RCS.

Baseline Measures
    Intent-to-Treat  
Number of Participants  
[units: participants]
  181  
Age  
[units: years]
Mean ± Standard Deviation
  56.6  ± 16.4  
Gender  
[units: participants]
 
Female     100  
Male     81  
Region of Enrollment  
[units: participants]
 
United States     152  
United Kingdom     29  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Navigation Performance   [ Time Frame: During Procedure ]

2.  Primary:   Evaluation of Major Complications   [ Time Frame: Seven Days (visit 3), except for any subject with an ongoing SAE that is related to the study will be scheduled for additional evaluations at 14 day intervals. ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Vice President, Clinical and Regulatory Affairs
Organization: Catheter Robotics, Inc.
phone: 973-426-0300
e-mail: research@catheterrobotics.com


No publications provided


Responsible Party: Catheter Robotics, Inc.
ClinicalTrials.gov Identifier: NCT01139814     History of Changes
Other Study ID Numbers: 2008-001-01
Study First Received: June 7, 2010
Results First Received: March 1, 2013
Last Updated: April 9, 2013
Health Authority: United States: Food and Drug Administration